[go: up one dir, main page]

MX2011006347A - Conjugados de oligosacaridos-proteinas. - Google Patents

Conjugados de oligosacaridos-proteinas.

Info

Publication number
MX2011006347A
MX2011006347A MX2011006347A MX2011006347A MX2011006347A MX 2011006347 A MX2011006347 A MX 2011006347A MX 2011006347 A MX2011006347 A MX 2011006347A MX 2011006347 A MX2011006347 A MX 2011006347A MX 2011006347 A MX2011006347 A MX 2011006347A
Authority
MX
Mexico
Prior art keywords
oligosaccharide
protein conjugates
conjugates
protein
formulae
Prior art date
Application number
MX2011006347A
Other languages
English (en)
Inventor
Robert J Miller
Clark Pan
Paul A Konowicz
Luis Z Avila
James E Stefano
Michael R Reardon
John Harrahy
Qun Zhou
Lauren Young
Patrick Finn
Xiaoyang Zheng
Joseph Kutzko
Yunxiang Zhu
Duncan Patterson
Andreas Peer
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2011006347A publication Critical patent/MX2011006347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

En el presente documento se proporcionan conjugados que comprenden una proteína y un oligosacárido de una de las fórmulas I-VI. También se proporcionan composiciones farmacéuticas que comprenden estos conjugados. Además, se proporcionan procedimientos para tratar un trastorno por depósito lisosomal en un mamífero con la administración de un conjugado de oligosacáridos-glicoproteínas.
MX2011006347A 2008-12-16 2009-12-11 Conjugados de oligosacaridos-proteinas. MX2011006347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12285108P 2008-12-16 2008-12-16
PCT/US2009/067775 WO2010075010A2 (en) 2008-12-16 2009-12-11 Oligosaccharide-protein conjugates

Publications (1)

Publication Number Publication Date
MX2011006347A true MX2011006347A (es) 2011-09-06

Family

ID=42138937

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015002855A MX364498B (es) 2008-12-16 2009-12-11 Conjugados de oligosacáridos-protenías.
MX2011006347A MX2011006347A (es) 2008-12-16 2009-12-11 Conjugados de oligosacaridos-proteinas.
MX2019004905A MX2019004905A (es) 2008-12-16 2011-06-14 Conjugados de oligosacaridos-proteinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015002855A MX364498B (es) 2008-12-16 2009-12-11 Conjugados de oligosacáridos-protenías.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019004905A MX2019004905A (es) 2008-12-16 2011-06-14 Conjugados de oligosacaridos-proteinas.

Country Status (20)

Country Link
US (5) US8835614B2 (es)
EP (5) EP2465542B1 (es)
JP (6) JP5658167B2 (es)
CN (5) CN112220930A (es)
BR (2) BRPI0923047B8 (es)
CA (2) CA2747230C (es)
CY (1) CY1121860T1 (es)
DK (3) DK2465542T3 (es)
ES (3) ES2735023T3 (es)
HR (2) HRP20150340T1 (es)
HU (2) HUE060974T2 (es)
IL (5) IL213595B (es)
LT (1) LT2889043T (es)
MX (3) MX364498B (es)
PL (2) PL2889043T3 (es)
PT (2) PT2889043T (es)
SI (2) SI2889043T1 (es)
SM (2) SMT201900375T1 (es)
TR (1) TR201909909T4 (es)
WO (1) WO2010075010A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP2457919B1 (en) * 2007-01-18 2019-06-05 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
HUE060974T2 (hu) * 2008-12-16 2023-04-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállítására
SI3482767T1 (sl) 2009-08-28 2022-03-31 Icahn School Of Medicine At Mount Sinai Encimska nadomestna terapija s povečevanjem odmerkov za zdravljenje pomanjkanja kisle sfingomielinaze
SG194486A1 (en) 2011-04-22 2013-12-30 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
EP2793922B1 (en) * 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
WO2013176239A1 (ja) * 2012-05-24 2013-11-28 国立大学法人 東京大学 酸化オリゴ糖で架橋したゲル材料
KR102741048B1 (ko) * 2014-09-30 2024-12-11 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
KR102725227B1 (ko) 2015-03-17 2024-10-31 엘레바 게엠베하 글리코실화된 리소좀 단백질, 생산 방법 및 용도
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
MX2018011951A (es) 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
KR20250017756A (ko) 2016-03-30 2025-02-04 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
WO2017170896A1 (ja) * 2016-03-30 2017-10-05 国立大学法人徳島大学 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
WO2017175082A1 (en) * 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
CN106366163A (zh) * 2016-10-31 2017-02-01 中国人民解放军第二军医大学 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用
CN106432371A (zh) * 2016-10-31 2017-02-22 中国人民解放军第二军医大学 β‑1,2‑D‑寡聚甘露糖蛋白缀合物及其制备方法和应用
HRP20230576T1 (hr) 2017-05-15 2023-09-01 Amicus Therapeutics, Inc. Rekombinantna ljudska kisela alfa-glukozidaza
EP3820473A4 (en) * 2018-07-09 2022-05-11 Merck Sharp & Dohme Corp. ENZYMATIC SYNTHESIS OF 4'-ETHINYL NUCLEOSIDE ANALOGUES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP7674740B2 (ja) * 2018-12-19 2025-05-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー リソソーム標的化のための二官能性分子ならびに関連する組成物および方法
CN115715218A (zh) 2020-02-08 2023-02-24 建新公司 治疗庞贝病的组合物和方法
WO2021257409A1 (en) 2020-06-14 2021-12-23 Genzyme Corporation Compositions and methods for treating late-onset pompe disease
KR20240036604A (ko) 2021-07-14 2024-03-20 리시아 테라퓨틱스, 인크. Asgpr 세포 표면 수용체 결합 화합물 및 접합체

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4749570A (en) 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS5936691A (ja) * 1982-08-24 1984-02-28 Rikagaku Kenkyusho 新規オリゴマンノシド及びその製造法
US5851991A (en) 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5206370A (en) 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5212298A (en) 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5583042A (en) 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5312903A (en) * 1990-06-01 1994-05-17 E. I. Du Pont De Nemours And Company Lysine-glycosylated recombinant interleukin-2
US5677440A (en) 1990-07-16 1997-10-14 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2073511A1 (en) 1990-11-14 1992-05-29 Matthew R. Callstrom Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
AU1676992A (en) 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
CZ283361B6 (cs) * 1991-12-20 1998-03-18 Novo Nordisk A/S Farmaceutický přípravek obsahující růstový hormon a histidin
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
FR2721612B1 (fr) 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5747471A (en) 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
EP0850313B8 (en) 1995-09-08 2009-07-29 Genzyme Corporation Improved aav vectors for gene therapy
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7141676B1 (en) 1996-02-08 2006-11-28 University Of Washington Water soluble multi-biotin-containing compounds
WO1997034623A1 (en) * 1996-03-21 1997-09-25 Transcell Technologies, Inc. Solid phase lipoglycopeptide library, compositions and methods
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
AUPO190596A0 (en) 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
CN1268741C (zh) 1996-09-13 2006-08-09 超卡里奥迪克治疗学股份有限公司 半乳糖苷酶a缺乏症的治疗
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
CA2246760C (en) 1997-01-21 2012-01-10 Pasteur Merieux Serums & Vaccins Polysaccharide-peptide-conjugates
US5925628A (en) 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP2147681A1 (en) 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
SE513149C2 (sv) 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
CA2318737A1 (en) 1998-02-17 1999-08-19 Genzyme Corporation Methods for pseudoadenoviral vector production
JP2002505085A (ja) 1998-02-17 2002-02-19 ジェンザイム・コーポレイション 精製ａａｖベクターの生産方法
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6538117B1 (en) 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
US6399575B1 (en) 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
ATE234626T1 (de) 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
ATE360082T1 (de) 1999-11-16 2007-05-15 Genzyme Corp Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
AU2001238346A1 (en) 2000-02-15 2001-08-27 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US20010031741A1 (en) 2000-02-17 2001-10-18 Robin Ziegler Methods for treatment of lysosomal storage diseases
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040067527A1 (en) 2000-07-26 2004-04-08 Sara Lavi Intracellular delivery system for protein phosphatases and other polypeptides
EP1315559B1 (en) 2000-08-18 2006-03-22 Massachusetts Institute Of Technology Apparatus and methods for the automated synthesis of oligosaccharides
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
IL158623A0 (en) 2001-04-30 2004-05-12 Symbiontics Inc Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2001090139A2 (en) 2001-05-07 2001-11-29 Supratek Pharma Inc. A ligand for enhancing oral and cns delivery of biological agents
ES2395463T3 (es) 2001-07-16 2013-02-15 Genzyme Corporation Un inhibidor de N-acilesfingosina glucosiltransferasa
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ES2466024T3 (es) 2001-10-10 2014-06-09 Ratiopharm Gmbh Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
WO2003045928A1 (en) 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
AU2002351199A1 (en) 2001-11-28 2003-06-10 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
ES2545619T3 (es) 2003-01-31 2015-09-14 The Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1653996A2 (en) 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
AU2005209303A1 (en) 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
WO2008029281A2 (en) * 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
EP2457919B1 (en) 2007-01-18 2019-06-05 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
HUE060974T2 (hu) 2008-12-16 2023-04-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállítására
US12285108B1 (en) 2024-08-08 2025-04-29 Frank R. Connors Shelf device with interchangeable faceplate

Also Published As

Publication number Publication date
BRPI0923047B1 (pt) 2020-11-24
MX364498B (es) 2019-04-29
IL270930A (en) 2020-01-30
PT2465542E (pt) 2015-04-16
ES2735023T3 (es) 2019-12-13
US12252504B2 (en) 2025-03-18
EP3608330A2 (en) 2020-02-12
HUE060974T2 (hu) 2023-04-28
CN105879047A (zh) 2016-08-24
HUE044381T2 (hu) 2019-10-28
CN112618724A (zh) 2021-04-09
EP3608330B1 (en) 2022-11-09
JP2017008098A (ja) 2017-01-12
SMT201500082B (it) 2015-07-09
EP2889043B1 (en) 2019-04-10
JP2021169467A (ja) 2021-10-28
IL284184A (en) 2021-07-29
US20150175643A1 (en) 2015-06-25
DK2465542T3 (en) 2015-04-27
US9493498B2 (en) 2016-11-15
CA3040973A1 (en) 2010-07-01
BRPI0923047B8 (pt) 2021-05-25
EP2376123A2 (en) 2011-10-19
JP2019112444A (ja) 2019-07-11
US8835614B2 (en) 2014-09-16
IL237932B (en) 2019-12-31
EP4212541A1 (en) 2023-07-19
LT2889043T (lt) 2019-07-10
SI2465542T1 (sl) 2015-05-29
US20200216485A1 (en) 2020-07-09
US10464962B2 (en) 2019-11-05
HRP20191102T1 (hr) 2019-09-20
BR122020010601B8 (pt) 2021-07-27
JP2012512313A (ja) 2012-05-31
PL2889043T3 (pl) 2019-09-30
CN112220930A (zh) 2021-01-15
PL2465542T3 (pl) 2015-06-30
EP2889043A2 (en) 2015-07-01
BR122020010601B1 (pt) 2021-02-23
CN102369023A (zh) 2012-03-07
DK3608330T3 (da) 2023-02-06
SI2889043T1 (sl) 2019-08-30
US20220242899A1 (en) 2022-08-04
CA2747230C (en) 2019-06-11
EP2465542A1 (en) 2012-06-20
WO2010075010A3 (en) 2011-01-06
CA2747230A1 (en) 2010-07-01
JP7590515B2 (ja) 2024-11-26
IL284184B2 (en) 2023-06-01
US20180002365A1 (en) 2018-01-04
PT2889043T (pt) 2019-07-16
IL237932A0 (en) 2015-05-31
EP2889043A3 (en) 2015-07-22
CN103432566A (zh) 2013-12-11
DK2889043T3 (da) 2019-07-15
HRP20150340T1 (hr) 2015-07-31
IL237933A0 (en) 2015-05-31
EP3608330A3 (en) 2020-05-13
US11279725B2 (en) 2022-03-22
BRPI0923047A2 (pt) 2015-12-08
HK1171697A1 (en) 2013-04-05
JP5658167B2 (ja) 2015-01-21
IL213595B (en) 2018-02-28
CY1121860T1 (el) 2020-07-31
ES2534056T3 (es) 2015-04-17
SMT201900375T1 (it) 2019-09-09
ES2937017T3 (es) 2023-03-23
TR201909909T4 (tr) 2019-07-22
IL213595A0 (en) 2011-07-31
US20110300120A1 (en) 2011-12-08
JP2014139204A (ja) 2014-07-31
JP2023164869A (ja) 2023-11-14
EP2465542B1 (en) 2015-01-21
HK1210413A1 (en) 2016-04-22
MX2019004905A (es) 2020-11-12
IL270930B (en) 2021-07-29
JP6659503B2 (ja) 2020-03-04
WO2010075010A2 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
MX2019004905A (es) Conjugados de oligosacaridos-proteinas.
EP4293112A3 (en) Oligosaccharides comprising an aminooxy group and conjugates thereof
MX391454B (es) Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
MX349749B (es) Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico.
IN2012DN04908A (es)
EP2170054A4 (en) TARGETING CONJUGATES WITH ACTIVE SUBSTANCES ENCAPLED IN CYCLODEXTRIN POLYMERS
EP2350273A4 (en) COMPOSITIONS OF MANIPULATED HUMAN ARGINAS AND METHOD FOR THE TREATMENT OF CANCER
MX2018013333A (es) Composiciones de nucleasas terapeuticas y metodos.
BRPI0917000A2 (pt) proteínas conjugadas com eficácia in vivo prolongada
WO2010059253A3 (en) Methods and compositions for localized agent delivery
DK2268317T3 (da) Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme
EP1968622A4 (en) MICRO-RNA EXPRESSION ANOMALIES IN PANCREAS AND AZINUS TUMORS
MX2010004110A (es) Formulacion para mejorar la funcion gastrointestinal.
WO2008089339A3 (en) Oligosaccharide conjugates for cellular targeting
AR061155A1 (es) Preparaciones liofilizadas de pantoprazol sodico para inyeccion
CY1116394T1 (el) Συζευγματα ολιγοσακχαριτη-πρωτεϊνης
BRPI0917819B8 (pt) compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado
MX2010006170A (es) Composicion farmaceutica para la limpieza del intestino.
CY1114320T1 (el) Ολιγοσακχαριτες που περιλαμβανουν αμινοοξυ-ομαδα και συζευγματα αυτων
IL202849A0 (en) Targeting conjugates comprising active agent encapsulated in cyclodextrin-containing polymers
SI2121713T1 (sl) Oligosaharidi, ki obsegajo aminooksi skupino, in njihovi konjugati

Legal Events

Date Code Title Description
FG Grant or registration